295 related articles for article (PubMed ID: 35395951)
1. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
[TBL] [Abstract][Full Text] [Related]
2. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA; Schrezenmeier E; Diebold M; Halloran PF; Schatzl M; Schranz S; Haindl S; Kasbohm S; Kainz A; Eskandary F; Doberer K; Patel UD; Dudani JS; Regele H; Kozakowski N; Kläger J; Boxhammer R; Amann K; Puchhammer-Stöckl E; Vietzen H; Beck J; Schütz E; Akifova A; Firbas C; Gilbert HN; Osmanodja B; Halleck F; Jilma B; Budde K; Böhmig GA
N Engl J Med; 2024 May; ():. PubMed ID: 38804514
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.
Zhang H; Zheng C; Li X; Fu Q; Li J; Su Q; Zeng L; Liu Z; Wang J; Huang H; Xu B; Ye M; Liu L; Wang C
Front Immunol; 2020; 11():342. PubMed ID: 32184785
[TBL] [Abstract][Full Text] [Related]
6. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
8. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic challenge of late antibody-mediated kidney allograft rejection.
Böhmig GA; Eskandary F; Doberer K; Halloran PF
Transpl Int; 2019 Aug; 32(8):775-788. PubMed ID: 30955215
[TBL] [Abstract][Full Text] [Related]
10. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
[TBL] [Abstract][Full Text] [Related]
11. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56
Bailly E; Macedo C; Ossart J; Louis K; Gu X; Ramaswami B; Bentlejewski C; Zeevi A; Randhawa P; Lefaucheur C; Metes D
Kidney Int; 2023 Oct; 104(4):707-723. PubMed ID: 37220805
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the Natural Killer Cell Receptor NKG2C Encoding
Vietzen H; Döhler B; Tran TH; Süsal C; Halloran PF; Eskandary F; Herz CT; Mayer KA; Kozakowski N; Wahrmann M; Ely S; Haindl S; Puchhammer-Stöckl E; Böhmig GA
Front Immunol; 2022; 13():829228. PubMed ID: 35401541
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials.
Mayer KA; Budde K; Jilma B; Doberer K; Böhmig GA
Expert Opin Emerg Drugs; 2022 Jun; 27(2):151-167. PubMed ID: 35715978
[TBL] [Abstract][Full Text] [Related]
18. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment.
Mayer KA; Doberer K; Eskandary F; Halloran PF; Böhmig GA
Curr Opin Organ Transplant; 2021 Feb; 26(1):97-105. PubMed ID: 33315763
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Mediated Rejection Due to Preexisting versus
Aubert O; Loupy A; Hidalgo L; Duong van Huyen JP; Higgins S; Viglietti D; Jouven X; Glotz D; Legendre C; Lefaucheur C; Halloran PF
J Am Soc Nephrol; 2017 Jun; 28(6):1912-1923. PubMed ID: 28255002
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
